“[W]e are working with the FDA to accelerate our regulatory approval target action date,” Mylan chief executive Heather Bresch said after a federal-district court in West Virginia ruled that the patent on Biogen’s multiple sclerosis drug Tecfidera was invalid.Mylan’s willingness to launch at risk could be a bet that an appeals court will show the usual deference to the fact findings of U.S. District Judge Irene Keeley.